Bavarian Nordic (BVNRY) Stock Price, News & Analysis

Company Overview

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Key Stats

• Today's Range: $12.39 to $12.41
• 50-Day Range: $8.66 to $12.47
• 52-Week Range: $6.60 to $14.60
• Volume: 2,432 shs
• Average Volume: 7,946 shs
• Market Capitalization: $2.93 billion
• P/E Ratio: 15.48
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVNRY Stock Analysis - Frequently Asked Questions

How have BVNRY shares performed this year?

Bavarian Nordic's stock was trading at $8.7060 at the start of the year. Since then, BVNRY shares have increased by 42.3% and is now trading at $12.3850.

How were Bavarian Nordic's earnings last quarter?

Bavarian Nordic (OTCMKTS:BVNRY) released its quarterly earnings results on Friday, May, 9th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $189.89 million for the quarter. Bavarian Nordic had a net margin of 21.11% and a trailing twelve-month return on equity of 11.89%.

How do I buy shares of Bavarian Nordic?

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/15/2025
• Next Earnings (Estimated): 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BVNRY
• CIK: N/A
• Web: www.bavarian-nordic.com
• Phone: (453) 326-8383
• Fax: 45-3326-8380
• Employees: 1,611
• Year Founded: 1994

Profitability

• EPS (Trailing Twelve Months): $0.80
• Trailing P/E Ratio: 15.47
• Forward P/E Ratio: 18.47
• P/E Growth: N/A
• Net Income: $143.26 million
• Net Margins: 21.11%
• Pretax Margin: 21.18%
• Return on Equity: 11.89%
• Return on Assets: 9.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.81
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $829.12 million
• Price / Sales: 3.53
• Cash Flow: $1.01 per share
• Price / Cash Flow: 12.31
• Book Value: $6.99 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 236,570,000
• Free Float: N/A
• Market Cap: $2.93 billion
• Optionable: Not Optionable
• Beta: 1.36